BIO-TECHNE CORP's ticker is TECH and the CUSIP is 09073M104. A total of 431 filers reported holding BIO-TECHNE CORP in Q4 2020. The put-call ratio across all filers is 1.11 and the average weighting 0.2%.
About BIO-TECHNE CORP
Bio-Techne Corp is a leading provider of innovative life science research tools and diagnostic solutions. The company is headquartered in Minneapolis, Minnesota, and has operations in over 50 countries worldwide. Bio-Techne's products and services are used by researchers and clinicians in a wide range of fields, including cancer research, stem cell research, and immunology.
Bio-Techne's success is due in large part to its commitment to innovation and customer service. The company invests heavily in research and development, and has a team of over 1,000 scientists working to develop new products and technologies. Bio-Techne also has a strong focus on customer service, with a dedicated team of technical support specialists available to assist customers with any questions or issues they may have.
In addition to its research tools and diagnostic solutions, Bio-Techne also has a growing portfolio of clinical diagnostic products. The company's Exosome Diagnostics subsidiary is a leader in the development of liquid biopsy tests for cancer diagnosis and monitoring.
Bio-Techne's leadership team is comprised of experienced executives with a track record of success in the life sciences industry. Charles Kummeth, the company's CEO, has been with Bio-Techne since 2013 and has overseen significant growth and expansion during his tenure.
Overall, Bio-Techne is a company with a strong reputation for innovation, customer service, and leadership in the life sciences industry. With a growing portfolio of products and services, the company is well-positioned for continued success in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $45,898,580 | +3.0% | 674,285 | +23.6% | 0.47% | +8.1% |
| Q2 2023 | $44,540,512 | -13.6% | 545,639 | -21.5% | 0.43% | -16.3% |
| Q1 2023 | $51,577,111 | +37.6% | 695,203 | +53.8% | 0.52% | +31.0% |
| Q4 2022 | $37,471,208 | +30.0% | 452,114 | +345.4% | 0.39% | +20.9% |
| Q3 2022 | $28,825,000 | -13.3% | 101,498 | +5.9% | 0.33% | -4.7% |
| Q2 2022 | $33,229,000 | -3.3% | 95,860 | +20.8% | 0.34% | +17.1% |
| Q1 2022 | $34,371,000 | -13.1% | 79,371 | +3.8% | 0.29% | -1.4% |
| Q4 2021 | $39,547,000 | +3.4% | 76,443 | -3.1% | 0.30% | +3.5% |
| Q3 2021 | $38,237,000 | -33.3% | 78,909 | -38.0% | 0.29% | -27.4% |
| Q2 2021 | $57,299,000 | -16.7% | 127,258 | -29.4% | 0.39% | -14.9% |
| Q1 2021 | $68,826,000 | +13.7% | 180,207 | -5.4% | 0.46% | -7.4% |
| Q4 2020 | $60,521,000 | +15.5% | 190,586 | -9.9% | 0.50% | -11.5% |
| Q3 2020 | $52,387,000 | -5.8% | 211,467 | +0.4% | 0.56% | -7.8% |
| Q2 2020 | $55,609,000 | +31.5% | 210,584 | -5.6% | 0.61% | +6.4% |
| Q1 2020 | $42,282,000 | -14.3% | 222,984 | -0.8% | 0.58% | +30.6% |
| Q4 2019 | $49,357,000 | -3.1% | 224,852 | -13.6% | 0.44% | -6.4% |
| Q3 2019 | $50,922,000 | -1.3% | 260,245 | +5.2% | 0.47% | +1.1% |
| Q2 2019 | $51,581,000 | -2.1% | 247,404 | -6.8% | 0.47% | +4.7% |
| Q1 2019 | $52,703,000 | +21.9% | 265,439 | -11.2% | 0.44% | +14.7% |
| Q4 2018 | $43,248,000 | -37.4% | 298,839 | -11.7% | 0.39% | -18.5% |
| Q3 2018 | $69,061,000 | -4.8% | 338,352 | -31.0% | 0.48% | -5.2% |
| Q2 2018 | $72,578,000 | -15.8% | 490,555 | -14.0% | 0.50% | -16.7% |
| Q1 2018 | $86,146,000 | +6.8% | 570,355 | -8.4% | 0.60% | +12.3% |
| Q4 2017 | $80,674,000 | +1.3% | 622,726 | -5.5% | 0.54% | +1.7% |
| Q3 2017 | $79,668,000 | -7.2% | 659,009 | -9.8% | 0.53% | -7.2% |
| Q2 2017 | $85,817,000 | +4.9% | 730,359 | -9.3% | 0.57% | +6.4% |
| Q1 2017 | $81,814,000 | +2.6% | 804,859 | +3.8% | 0.54% | +4.7% |
| Q4 2016 | $79,720,000 | -1.8% | 775,259 | +4.6% | 0.51% | -4.5% |
| Q3 2016 | $81,179,000 | -6.1% | 741,359 | -3.2% | 0.54% | -6.3% |
| Q2 2016 | $86,411,000 | +9.5% | 766,259 | -8.2% | 0.57% | +14.7% |
| Q1 2016 | $78,901,000 | -3.5% | 834,759 | -8.1% | 0.50% | +2.0% |
| Q4 2015 | $81,771,000 | +8.3% | 908,569 | +11.2% | 0.49% | +22.0% |
| Q3 2015 | $75,519,000 | +51.7% | 816,779 | +61.6% | 0.40% | +90.5% |
| Q2 2015 | $49,773,000 | +23.6% | 505,459 | +25.9% | 0.21% | +38.2% |
| Q1 2015 | $40,255,000 | -28.8% | 401,385 | -34.4% | 0.15% | -22.4% |
| Q4 2014 | $56,533,000 | – | 611,825 | – | 0.20% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Broadcrest Asset Management, LLC | 275,000 | $18,719,250 | 20.14% |
| Montanaro Asset Management Ltd | 408,800 | $27,827,016 | 4.90% |
| Sandhill Capital Partners LLC | 613,061 | $41,731,091 | 3.90% |
| Pembroke Management, LTD | 365,611 | $24,887,141 | 3.40% |
| DF DENT & CO INC | 3,349,047 | $227,969,648 | 3.34% |
| Brown Capital Management | 3,158,004 | $214,965,332 | 3.30% |
| Ownership Capital B.V. | 1,786,273 | $121,591,603 | 3.05% |
| STONE RUN CAPITAL, LLC | 86,335 | $5,876,823 | 2.88% |
| Jackson Square Partners, LLC | 1,260,547 | $85,805,434 | 2.87% |
| Summit Creek Advisors LLC | 284,681 | $19,378,236 | 2.64% |